|By Marketwired .||
|January 10, 2014 05:05 PM EST||
TORONTO, ONTARIO -- (Marketwired) -- 01/10/14 -- Trimel Pharmaceuticals Corporation (TSX: TRL) today announced the retirement of Mr. Bruce Brydon as Chair of the Board of Directors and as a Director.
The Board has appointed Mr. Ian Ihnatowycz, currently a Director of Trimel, as Chair of the Board of Directors. Both changes are effective January 15, 2014.
Mr. Brydon stated, "As we enter a new year, I have given considerable thought to my personal circumstances - now located in Western Canada away from Trimel's base of operations - as well as the next phase of Trimel's development and succession. Accordingly, I have decided that now is the time to step aside and pass on my duties to the new Chair, whose excellent leadership skills will benefit the company and its shareholders."
Ian Ihnatowycz is the President and Chief Executive Officer of First Generation Capital Inc., a private investment holding company and one of Trimel's major shareholders. He founded Acuity in 1990 and served as President and Chief Executive Officer of Acuity Investment Management Inc. and Acuity Funds Ltd. until its sale in 2011. Mr. Ihnatowycz has served on the boards of numerous public and private companies as well as a variety of not-for-profit and professional organizations. He is currently a member of the Board of Directors of Zymeworks Inc., Myca Health Inc., and Real Imaging Ltd., all operating in the life sciences sector, Fulcrum Management Solutions Ltd., and the Royal Conservatory of Music. Additionally, Mr. Ihnatowycz is a member of the Ivey Advisory Board and the Ian. O. Ihnatowycz Institute for Leadership Advisory Board, both at the Ivey Business School. Mr. Ihnatowycz's degrees and professional designations include a B.Sc. (University of Toronto), M.B.A. (Ivey Business School), CFA and Chartered Director. He was recently presented with an Honorary Doctor of Laws degree from Western University.
"On behalf of the Board, I would like to thank Bruce Brydon for his leadership and years of dedicated service to Trimel as Chair and founding CEO," stated Mr. Ihnatowycz. "During his tenure with the company, Bruce has successfully launched and led Trimel through its initial development phase. We wish him all the best in the future."
Trimel is a specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders. An NDA for CompleoTRT, a product utilizing Trimel's licensed bioadhesive intranasal gel technology, has been accepted for review by the FDA for regulatory approval in the United States. For more information, please visit www.trimelpharmaceuticals.com.